Blog

Osteoporos Int. 2016 Mar;27(3):861-71. doi: 10.1007/s00198-015-3331-7. Epub 2015 Sep 29 Further clinical studies with these medications are needed to fully understand their effects on fracture healing in order to simultaneously treat fragility fractures and underlying … Leer más

Chronic abnormal phosphaturia explains, at least in part, progressive bone loss during TDF therapy. These data suggest that tubular dysfunction leads to an altered equilibrium between phosphatemia, phosphaturia and bone as mechanism of progressive BMD … Leer más

Our data confirm a clinically relevant bone loss associated with aromatase inhibitors (AI) therapy amongst non-users of preventative bisphosphonates. We further report on the importance of BMD monitoring as well as calcium and 25(OH)vitD supplementation … Leer más

There was no significant difference between suffering a second hip fracture and following osteoporosis treatment, using psychotropic drugs or being institutionalised.

Unintentional weight loss at baseline was associated with a significantly increased risk of fracture of the clavicle, wrist, spine, rib, hip, and pelvis for up to 5 years following weight loss. This increase is seen … Leer más

Calcidiol is faster and 3-6 times more potent to obtain serum levels of 25(OH)D in the medium to long term.

The introduction and/or expansion of orthogeriatric and FLS models of post-hip fracture care has a beneficial effect on subsequent mortality. No evidence for a reduction in second hip fracture rate was found.

An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Within a strategy of a disease modifying approach to inflammatory disease, short durations of moderate doses of … Leer más

In our study, the presence of the ‘s’ allele of the COL1A1 Sp1 polymorphism in individuals with epilepsy was related to lower bone BMD (lumbar and femoral). This relationship seemed to be further apparent in … Leer más